Alnylam Pharmaceuticals (ALNY) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sanofi (SNY) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, losing 17.6% versus a loss of 49.1%. Over five years, ALNY leads with a +11.6% price change compared with -17.6% for SNY. Sanofi is the larger company by market cap ($96.01 billion vs $31.13 billion), about 3.1 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 18.7x for Alnylam Pharmaceuticals). Sanofi pays a dividend yielding 10.28%, while Alnylam Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | SNY |
|---|---|---|
| Share price | $232.68 | $40.07 |
| Market cap | $31.13B | $96.01B |
| 1-day change | +3.63% | -0.40% |
| YTD return | -41.49% | -16.98% |
| 1-year return | -49.08% | -17.56% |
| 5-year return | +11.57% | -17.65% |
| P/E ratio (TTM) | 37.83 | 21.20 |
| Forward P/E | 18.73 | 7.42 |
| EPS (TTM) | $6.15 | $1.89 |
| Dividend yield | 0.00% | 10.28% |
| Annual dividend | $0.00 | $4.12 |
| Revenue (latest FY) | $3.71B | — |
| Revenue growth (YoY) | +65.19% | — |
| Net income (latest FY) | $313.75M | — |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | — |
| 52-week high | $495.55 | $52.68 |
| 52-week low | $197.81 | $39.18 |
| Distance from 52-week high | -53.05% | -23.94% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +59.50% | +33.79% |
| Average volume | 1.78M | 2.87M |
| Shares outstanding | 133.81M | 2.40B |
| Employees | 2,500 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanofi is about 3.1 times larger than Alnylam Pharmaceuticals by market value ($96.01B vs $31.13B).
- SNY has outperformed ALNY by 31.5 percentage points over the past year.
- Alnylam Pharmaceuticals trades at a higher earnings multiple (37.8x vs 21.2x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.28% vs 0.00%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
ALNY vs SNY FAQ
Which is bigger, Alnylam Pharmaceuticals or Sanofi?
Sanofi (SNY) is larger, with a market capitalization of $96.01B compared with $31.13B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or SNY?
SNY returned -17.56% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or SNY?
SNY has the lower trailing P/E at 21.2, versus 37.8 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Alnylam Pharmaceuticals or Sanofi?
Sanofi pays a dividend yielding 10.28%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.